Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

NCT03245008 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT03245008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03245008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
September 8, 2017
Completion date
March 9, 2021
Enrollment
626 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee / osteoarthritis, hip